Payment overview · 2025
General Payments
$664.48
25 reported records · 11 companies
Healthcare provider profile · identity verified
Fred K Uthoff
Allopathic & Osteopathic Physicians|Family Medicine · SIKESTON, MO · NPI 1639164965
Verified facts
What the public records show
CMS Open Payments records show Fred K Uthoff received $664.48 in general payments during 2025 across 25 reported records.
Amgen Inc. accounted for 33.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Voquezna.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Synthroid by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Eliquis by this doctor in 2024.
Phathom Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VOQUEZNA as an associated drug or biological on 90302 records involving 33442 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Voquezna by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $219.44 | 33.0% | 7 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$120.48 | 18.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $92.96 | 14.0% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.58 | 9.4% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $46.02 | 6.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.70 | 6.6% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $17.28 | 2.6% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $17.15 | 2.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.67 | 2.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.38 | 2.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.82 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $664.48 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $206.89 | 6 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $120.48 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $92.96 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $62.58 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $46.02 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.70 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.70 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.41 | 5 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $12.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 102 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VOQUEZNA voquezna |
2025 | Voquezna | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
94 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
102 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
220 | 25 |
| Phathom Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | VOQUEZNA open payments reported associated product |
CMS Open Payments — General Payments 90302 supporting records · 33442 recipient NPIs · example record 1219216983 |
Voquezna · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 771 | 148 |
| Amlodipine Besylate | Amlodipine Besylate | 525 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 495 | 93 |
| Tramadol Hcl | Tramadol Hcl | 468 | 84 |
| Alprazolam | Alprazolam | 467 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 400 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 387 | 76 |
| Gabapentin | Gabapentin | 341 | 57 |
| Furosemide | Furosemide | 273 | 54 |
| Potassium Chloride | Potassium Chloride | 259 | 55 |
| Omeprazole | Omeprazole | 250 | 45 |
| Lisinopril | Lisinopril | 232 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 228 | 42 |
| Eliquis | Apixaban | 220 | 25 |
| Telmisartan | Telmisartan | 201 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 193 | 52 |
| Montelukast Sodium | Montelukast Sodium | 189 | 37 |
| Allopurinol | Allopurinol | 186 | 29 |
| Losartan Potassium | Losartan Potassium | 171 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 168 | 31 |
| Metformin Hcl | Metformin Hcl | 166 | 30 |
| Carvedilol | Carvedilol | 165 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 160 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 154 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 146 | 19 |
| Sertraline Hcl | Sertraline Hcl | 143 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 28 |
| Clonazepam | Clonazepam | 136 | 18 |
| Mounjaro | Tirzepatide | 124 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 119 | 23 |
| Metformin Hcl Er | Metformin Hcl | 118 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 115 | 24 |
| Diazepam | Diazepam | 114 | 20 |
| Trazodone Hcl | Trazodone Hcl | 113 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 110 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 109 | 13 |
| Glimepiride | Glimepiride | 109 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 32 |
| Alendronate Sodium | Alendronate Sodium | 104 | 19 |
| Ozempic | Semaglutide | 102 | 12 |
| Meloxicam | Meloxicam | 99 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 99 | 13 |
| Ezetimibe | Ezetimibe | 98 | 27 |
| Simvastatin | Simvastatin | 95 | 14 |
| Linzess | Linaclotide | 94 | 15 |
| Lorazepam | Lorazepam | 90 | 20 |
| Chlorthalidone | Chlorthalidone | 89 | 20 |
| Buspirone Hcl | Buspirone Hcl | 82 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 80 | 15 |
| Jardiance | Empagliflozin | 78 | suppressed |
| Xarelto | Rivaroxaban | 78 | 11 |
| Finasteride | Finasteride | 70 | 16 |
| Farxiga | Dapagliflozin Propanediol | 68 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 63 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 59 | 11 |
| Gemtesa | Vibegron | 59 | suppressed |
| Ramipril | Ramipril | 58 | suppressed |
| Spironolactone | Spironolactone | 57 | 14 |
| Propranolol Hcl | Propranolol Hcl | 56 | 12 |
| Mirtazapine | Mirtazapine | 55 | 11 |
| Synthroid | Levothyroxine Sodium | 55 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 54 | 24 |
| Vascepa | Icosapent Ethyl | 54 | suppressed |
| Pregabalin | Pregabalin | 53 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 37 |
| Estradiol | Estradiol | 48 | 12 |
| Ondansetron Odt | Ondansetron | 47 | 16 |
| Levetiracetam | Levetiracetam | 46 | suppressed |
| Celecoxib | Celecoxib | 45 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 45 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | suppressed |
| Torsemide | Torsemide | 44 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 32 |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 42 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 40 | 40 |
| Terazosin Hcl | Terazosin Hcl | 39 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Famotidine | Famotidine | 36 | 11 |
| Ibuprofen | Ibuprofen | 36 | 11 |
| Promethazine Hcl | Promethazine Hcl | 36 | 11 |
| Topiramate | Topiramate | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Repatha Sureclick | Evolocumab | 35 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 25 |
| Fenofibrate | Fenofibrate,micronized | 33 | suppressed |
| Irbesartan | Irbesartan | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Risperidone | Risperidone | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Olanzapine | Olanzapine | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 25 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 18 |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 18 |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Prednisone | Prednisone | 25 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Cephalexin | Cephalexin | 24 | 18 |
| Repatha Syringe | Evolocumab | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 16 |
| Amoxicillin | Amoxicillin | 18 | 16 |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Eplerenone | Eplerenone | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 18 | suppressed |
| Haloperidol | Haloperidol | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 17 | suppressed |
| Voquezna | Vonoprazan Fumarate | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 11 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $664.48 · 25 records | Amgen Inc. | ABRYSVO, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, EVENITY, GARDASIL 9, INCEPTIV, LEQVIO, NUPLAZID, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, REPATHA, Rybelsus, VOQUEZNA, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error